• If you are wondering whether Elanco Animal Health's current share price lines up with its underlying worth, this article will walk through the key numbers that matter for valuation.
• The stock last closed at US$23.36, with returns of 3.7% year to date and 109.7% over the past year, which may have changed how investors think about both its growth potential and risk.
• Recent coverage around Elanco has focused on its position in animal health and investor interest following its share price moves, giving more attention to how its portfolio and capital allocation choices could affect long term value. This context helps explain why the current valuation is getting more scrutiny than before.
• On Simply Wall St's valuation checks, Elanco scores a 6 out of 6 for potential undervaluation. Next, we will look at how different valuation methods stack up for the stock, then finish with a broader framework that can help you judge whether those models really fit your own view of value.

Elanco Animal Health delivered 109.7% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Elanco Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash Elanco Animal Health is expected to generate in the future and discounts each year’s estimate back to today, to arrive at an implied value per share.

For Elanco, the latest twelve month Free Cash Flow is about $354 million. Analysts have provided forecasts out to 2030, with Simply Wall St extending those projections further using its own assumptions. For example, projected Free Cash Flow for 2030 is $737 million, with intermediate years such as 2026 and 2027 sitting at $463.5 million and $527.75 million respectively, all in dollars and below the $1 billion mark.

Using these cash flow projections in a 2 Stage Free Cash Flow to Equity model produces an estimated intrinsic value of $36.89 per share. Compared with the recent share price of $23.36, this implies a 36.7% discount, which points to the stock trading below this model’s estimate of underlying value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 36.7%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Elanco Animal Health.

Approach 2: Elanco Animal Health Price vs Sales

For Elanco Animal Health, the preferred multiple is the Price to Sales (P/S) ratio, which can be useful when earnings are limited or volatile but revenue is more stable. Investors often use this to compare how much they are paying for each dollar of sales across similar businesses.

What counts as a “normal” or “fair” P/S ratio usually reflects how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk tends to justify a lower one.

Elanco currently trades on a P/S ratio of 2.46x. This sits below the Pharmaceuticals industry average of 3.87x and below the peer average of 3.51x. Simply Wall St also calculates a proprietary “Fair Ratio” of 4.47x for Elanco. This Fair Ratio estimates the P/S multiple that might be reasonable given factors such as the company’s earnings growth profile, profit margins, industry, market cap and specific risks, rather than relying only on broad peer or industry comparisons.

Because Elanco’s actual P/S of 2.46x is meaningfully below the Fair Ratio of 4.47x, the preferred multiple approach points to the shares trading below this model’s estimate of fair value.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Elanco Animal Health Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce Narratives, which are simple stories you build around your own assumptions for Elanco Animal Health’s future revenue, earnings and margins. You then link that story to a forecast and fair value on Simply Wall St’s Community page, and compare your Fair Value with the current price to decide whether the shares look attractive or not. The Narrative updates automatically when new earnings, news or guidance arrive. One investor might set out a confident Elanco story with a Fair Value of about US$35.81. Another, more cautious view could point to a Fair Value closer to US$14.39 or US$18.18 or even US$22.49. A third investor might see more upside potential at around US$29.84. All of these are different but equally valid ways to connect the same company to different expectations.

For Elanco Animal Health we have made it easy for you with previews of two leading Elanco Animal Health Narratives:

Each one links a clear story about the business to a Fair Value estimate, so you can quickly see which set of assumptions feels closer to your own view.

🐂 Elanco Animal Health Bull Case

Fair Value: US$35.81 per share

Implied discount to this Fair Value: about 34.8% relative to the last close of US$23.36

Revenue growth assumption: 15.02%

• Focuses on Elanco as a company that is now centered on its higher growth Innovation pillar, with products like Zenrelia and Credelio Quattro playing a key role in the story.
• Highlights margin expansion and balance sheet improvement, including a debt to equity ratio of 0.59, as important pillars of the thesis.
• Arrives at a US$35.81 Fair Value using a multi stage DCF that applies a 12% compound growth rate to Pet Health free cash flow and an 8.8% discount rate.

🐻 Elanco Animal Health Bear Case

Fair Value: US$22.49 per share

Implied premium to this Fair Value: about 3.9% relative to the last close of US$23.36

Revenue growth assumption: 4.75%

• Flags heavier R&D and marketing spend, patent expiries, regulatory pressures and customer shifts as potential headwinds for revenue quality and margins over time.
• Points to a debt load of more than US$3.4b and a net leverage ratio of 4x as constraints on flexibility, with higher interest costs and slower deleveraging as ongoing risks.
• Uses a discount rate of 6.98% and scenario work around analyst targets to support a Fair Value of US$22.49, with the argument that higher price targets may already bake in a demanding execution path.

If you want to go beyond these previews and see how other investors are joining the dots between Elanco’s products, margins and balance sheet, Curious how numbers become stories that shape markets? Explore Community Narratives.

Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.